Likewise, S100A1 is up-regulated in a disease-specific manner, so developing S100A1-specific inhibitors may aid in treating diabetes, neurological diseases, heart failure, and other cancers [5,10,11,12,13,14]. Here, S100A1 is linked to nervous system disorder.